Liver News and Research

RSS

Exelixis announces cabozantinib preclinical data on pancreatic cancer

Exelixis, Inc. today announced the company's lead compound, cabozantinib, is highlighted in a new peer-reviewed publication demonstrating that simultaneous inhibition of MET and VEGF signaling reduces tumor invasiveness and metastasis in preclinical models of pancreatic cancer.

26 Feb 2012

Article in journal Science proposes new look on killer diseases

The immune system protects from infections by detecting and eliminating invading pathogens. These two strategies form the basis of conventional clinical approaches in the fight against infectious diseases.

24 Feb 2012

Can-Fite receives FDA Orphan Drug Status for CF102 to treat hepatocellular carcinoma

Can-Fite BioPharma Ltd, a biotechnology company developing small molecule drugs for the treatment of inflammatory, and liver diseases, traded on the Tel Aviv Stock Exchange, announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Status for its drug candidate, CF102, for the treatment of hepatocellular carcinoma.

23 Feb 2012

Elevated levels of two TLRs can trigger heart disease and diabetes

UC Davis scientists have uncovered a key suspect in the destructive inflammation that underlies heart disease and diabetes. The new research shows elevated levels of a receptor present on leucocytes of the innate immune response in people at risk for these chronic diseases.

23 Feb 2012

Onyx reports total operating revenue of $237.0M for fourth quarter 2011

Onyx Pharmaceuticals, Inc. today reported its financial results for the full year and fourth quarter 2011. Onyx reported non-GAAP net income of $42.0 million, or $0.66 per diluted share, for the full year 2011 compared to non-GAAP net income of $39.2 million, or $0.63 per diluted share, for the same period in 2010.

23 Feb 2012

First-ever comparative analysis of antimalarial medicines at every step of the parasite's life cycle

MMV and partners have completed the first-ever comparative analysis of all currently available and in-development antimalarials in terms of the steps they target in the parasite's lifecycle. This information provides the missing pieces of the puzzle needed to develop future medicines able to block transmission of the parasite from person to person.

23 Feb 2012

Routine hepatitis C testing of the middle aged could save thousands of lives: CDC report

Increasing number of people are dying of damaged livers due to hepatitis C infection. Federal health officials are considering whether anyone born between 1945 and 1965 should get a one-time blood test to check if they are harboring the dangerous virus. Two-thirds of people with hepatitis C are in this age group, most unaware that a virus that takes a few decades to do its damage has festered since their younger days.

22 Feb 2012

IDOM researchers overturn textbook view of liver metabolism

A team led by researchers from the Institute for Diabetes, Obesity and Metabolism (IDOM) at the Perelman School of Medicine, University of Pennsylvania, has overturned a "textbook" view of what the body does after a meal.

22 Feb 2012

EMA grants positive scientific opinion for Pyramax to treat malaria

Pyramax-, a fixed-dose combination of pyronaridine and artesunate, becomes the first antimalarial to be granted a positive scientific opinion from the European Medicines Agency (EMA) under Article 58. This once daily, 3-day treatment is indicated for acute, uncomplicated Plasmodium falciparum and blood-stage Plasmodium vivax malaria in adults and children over 20 kg.

22 Feb 2012

Telomerase reactivation in malignant cells after genomic instability causes cancer progression

Inhibiting telomerase, an enzyme that rescues malignant cells from destruction by extending the protective caps on the ends of chromosomes, kills tumor cells but also triggers resistance pathways that allow cancer to survive and spread, scientists report in the Feb. 17 issue of Cell.

21 Feb 2012

New triple-therapies found cost-effective for chronic hepatitis C patients with advanced liver disease

A towering $60,000 bill, a year of fierce, flu-like symptoms and a running risk of depression are among the possible costs of two new hepatitis C treatments. But according to Stanford University health policy researchers, they might be worth it.

21 Feb 2012

Some answers about prescription psychiatric drugs

The circumstances of Whitney Houston's demise have dominated headlines and search trends since news outlets first reported of her death. Her struggle with addiction was covered extensively by the media, and even discussed candidly by Houston herself during several high-profile interviews.

20 Feb 2012

Defects in GPR120 protein may lead to obesity and liver disease

Defects in a protein that functions as a dietary fat sensor may be a cause of obesity and liver disease, according to a study published in the journal Nature, led by researchers at Imperial College London. The findings highlight a promising target for new drugs to treat obesity and metabolic disorders.

19 Feb 2012

Bristol-Myers Squibb awards 3 new grants to enhance HBV and HCV prevention, diagnosis and care

The Bristol-Myers Squibb Foundation has awarded three new grants to improve prevention, diagnosis and care of hepatitis B (HBV) and hepatitis C (HCV) in China and India as part of its Delivering Hope: Awareness, Prevention and Care umbrella program which is committed to reducing hepatitis-related health disparities in Asia.

19 Feb 2012

Arsenic found in baby formula containing organic brown rice syrup

Rice is among the plants that are efficient in taking up arsenic from the soil, environmental chemist Brian Jackson of Dartmouth College in Hanover, N.H., and his co-authors said in Thursday's issue of the journal Environmental Health Perspectives. Long-term exposure to extremely high levels of inorganic arsenic can increase the risk of lung, liver and bladder cancer as well as miscarriage and infertility.

18 Feb 2012

The 'nutritional magic' behind soy's heart health benefits

Nutrition science has regarded soy as a superfood with many health benefits for decades. In fact, "25 grams of soy protein per day, as part of a diet low in saturated fat and cholesterol, may reduce the risk of heart disease," according to the FDA.

18 Feb 2012

New, under-recognized, much more potent variant of common bacterium

University at Buffalo researchers are expressing concern about a new, under-recognized, much more potent variant of a common bacterium that has surfaced in the U.S.

18 Feb 2012

UB researchers express concern about a new variant of Klebsiella pneumoniae

University at Buffalo researchers are expressing concern about a new, under-recognized, much more potent variant of a common bacterium that has surfaced in the U.S.

18 Feb 2012

Nordion celebrates first anniversary of market launch of TheraSphere

Nordion Inc., a leading provider of products and services to the global health science market, today celebrated the first anniversary of the market introduction of TheraSphere, an innovative radioembolic liver cancer therapy, in the Republic of Turkey.

17 Feb 2012

Low choline intake increases risk of liver scarring in menopausal women with NAFLD

Menopausal women with non-alcoholic fatty liver disease (NAFLD) who don't consume enough of the essential nutrient choline appear to be at higher risk for liver scarring, according to research led by scientists at Johns Hopkins Children's Center.

17 Feb 2012